lazertinib news

All news on lazertinib (also known as LAZCLUZE and YH25448): plants, production capacities, investments and involved companies.

31 May 2026

Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.

Who will be producing lazertinib in the future?

Find out with chemXplore Alpha

Learn more